Patents by Inventor Chung-Ming Hsieh

Chung-Ming Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17
    Publication number: 20150344566
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: December 3, 2015
    Inventors: Chung-Ming HSIEH, Tariq GHAYUR, Carrie L. GOODREAU
  • Methods for transforming yeast
    Patent number: 9200270
    Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150337042
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 26, 2015
    Applicant: ABBVIE INC.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • IMMUNOBINDERS DIRECTED AGAINST SCLEROSTIN
    Publication number: 20150266977
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Application
    Filed: February 18, 2015
    Publication date: September 24, 2015
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yulia Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • Therapeutic DLL4 binding proteins
    Patent number: 9132190
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 15, 2015
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Dual specific binding proteins directed against IL-13 and IL-17
    Patent number: 9120870
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Tariq Ghayur, Carrie L. Goodreau
  • Therapeutic DLL4 binding proteins
    Patent number: 9115195
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: August 25, 2015
    Assignee: ABBVIE INC.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF
    Publication number: 20150183871
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
    Type: Application
    Filed: January 7, 2015
    Publication date: July 2, 2015
    Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
  • Amyloid-beta binding proteins
    Patent number: 9062101
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 23, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20150111251
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: September 25, 2014
    Publication date: April 23, 2015
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • Immunobinders directed against sclerostin
    Patent number: 8999331
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: April 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20150093387
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: August 22, 2014
    Publication date: April 2, 2015
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Antibodies against the RGM A protein and uses thereof
    Patent number: 8962803
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 24, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
  • Methods of RNA display
    Patent number: 8916504
    Abstract: The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: December 23, 2014
    Assignee: Abbvie Inc.
    Inventors: Chung-Ming Hsieh, Yuliya A. Kutskova, John E. Memmott
  • IL-17 BINDING PROTEINS
    Publication number: 20140356909
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 28, 2014
    Publication date: December 4, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-17 BINDING PROTEINS
    Publication number: 20140348856
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 25, 2014
    Publication date: November 27, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-17 BINDING PROTEINS
    Publication number: 20140348834
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 23, 2014
    Publication date: November 27, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-17 BINDING PROTEINS
    Publication number: 20140343267
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 20, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-17 BINDING PROTEINS
    Publication number: 20140335564
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 13, 2014
    Applicant: ABBVIE INC.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • TNF-? binding proteins
    Patent number: 8877194
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 4, 2014
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Carrie L. Goodreau, Sahana Bose, Achim Moeller, Tariq Ghayur